PRODUCT DEVELOPMENT

Biotie has a broad pipeline of novel, potentially first or best-in class products in clinical development

Our focus is on generating innovative, clinically differentiated medicines for the treatment of neurodegenerative and psychiatric diseases based on strong scientific, medical and commercial rationale. We aim to advance our products through Phase 2 before seeking a partnership with large pharma or biotech for late stage development and commercialization.   In situations where we believe we can be competitive, e.g. for specialty or orphan indications, we will progress our pipeline internally to registration, approval and market.  We have a dedicated team of scientists, in Europe and the US, with the drive and enthusiasm to deliver new medicines to patients.

PRODUCT PIPELINE

Product	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory / Commercial
SelincroTM (nalmefene)alcohol dependence opiod antagonist					EU MAA filing submitted 12/2011
Tozadenant (SYN115)Parkinson's disease adenosine A2a antagonist​			Phase 2b ongoing; data due H1 2013
1) SYN120AD/cognitive disorders 5-HT6 antagonist​	​	​	PET imaging study complete H1 2012 - Ready for Phase 2	​	​
​ VAP-1 antibody inflammatory / fibrotic disease VAP-1 antagonist, fully human​	​		​ Ready for Phase 2 -Seek partner     for large indications	​	​
​ Nepicastat (SYN117)2) PTSD 3) cocaine dependence DBH inhibitor​	​		​ 3) Results expected H2 2012	​	​
​ Ronomilast – COPD PDE4 inhibitor	​		​ Ready for Phase 2 -Seeking partner ​	​	​

1) Option agreement;
2) US Department of Defense conducting clinical study
3) US National Institute on Drug Abuse (NIDA) to fund clinical study

----------- 

Updated April 24, 2012